Dr. Meshinchi and Dr. Locatelli will serve as co-PIs.
Dr. Meshinchi, a pediatric oncologist and stem cell transplant physician at Fred Hutch, has 25 years of experience in AML biology and novel therapeutics. He led AML biology efforts for Children's Oncology Group (COG) for over two decades and identified several AML-specific targets, including mesothelin, now in clinical development.
Dr. Locatelli, Director of Pediatric Oncology at Bambino Gesù Pediatric Hospital (OPBG) in Italy, is one of the most renowned oncologists in the world. He is internationally recognized for his groundbreaking work in the treatment of pediatric leukemias, hematopoietic stem cell transplantation, and immunotherapies including CAR-T cell therapy. As chair of the Italian Association for Pediatric Hematology and Oncology (AIEOP) AML working party, he has positioned OPBG at the forefront of early-phase CAR-T trials for pediatric cancers, offering hope to children with otherwise untreatable cancers.